Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ISM3091 |
| Synonyms | |
| Therapy Description |
ISM3091 inhibits USP1, which potentially results in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2023) 83 (7_Supplement): 502). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ISM3091 | ISM 3091|ISM-3091|XL309 | USP1 inhibitor 7 | ISM3091 inhibits USP1, which potentially results in decreased tumor cell proliferation and reduced tumor growth (Cancer Res (2023) 83 (7_Supplement): 502). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05932862 | Phase I | ISM3091 + Olaparib ISM3091 | A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Recruiting | USA | 0 |